Uptake of gonadotrophin‐releasing hormone agonists for prevention of premature ovarian insufficiency in women undergoing chemotherapy: an <scp>Australian</scp> single‐centre study
One-quarter of eligible patients did not have a documented discussion regarding goserelin, despite the negative consequences of POI. Efforts are needed to increase the discussion and use of goserelin in all premenopausal women regardless of their fertility interests and to ensure timely administration in those who choose to receive it.
Authors
- C Stern
- Devchand Paul
- Nora Lee (ORCID: https://orcid.org/0000-0001-7047-308X)
- Kelly‐Anne Phillips (ORCID: https://orcid.org/0000-0002-0475-1771)
- Genia Rozen (ORCID: https://orcid.org/0000-0003-1210-1645)
- Wanyuan Cui (ORCID: https://orcid.org/0000-0002-5077-6814)
- Felicity C. Martin
- Jing Xie (ORCID: https://orcid.org/0000-0002-3194-9273)
- Sarah Price (ORCID: https://orcid.org/0000-0001-7722-3171)
Institutions
- The Royal Melbourne Hospital (AU)
- Royal Women's Hospital (AU)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Victorian Comprehensive Cancer Centre (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1111/imj.16564
- Primary Topic
- Reproductive Biology and Fertility
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health and Medical Research Council